GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (XMAD:GRF) » Definitions » Other Long Term Assets

Grifols (XMAD:GRF) Other Long Term Assets : €597 Mil (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Grifols Other Long Term Assets?

Grifols's other long-term assets for the quarter that ended in Dec. 2023 was €597 Mil.

Grifols's quarterly other long-term assets increased from Jun. 2023 (€219 Mil) to Sep. 2023 (€297 Mil) and increased from Sep. 2023 (€297 Mil) to Dec. 2023 (€597 Mil).

Grifols's annual other long-term assets increased from Dec. 2021 (€251 Mil) to Dec. 2022 (€321 Mil) and increased from Dec. 2022 (€321 Mil) to Dec. 2023 (€597 Mil).

Grifols Other Long Term Assets Historical Data

The historical data trend for Grifols's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Other Long Term Assets Chart

Grifols Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 232.44 237.04 251.44 320.93 597.36

Grifols Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 320.93 219.47 296.95 597.36

Grifols Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Grifols (XMAD:GRF) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (XMAD:GRF) » Definitions » Other Long Term Assets
Comparable Companies
XMAD:AEDAS XMAD:NEA XMAD:BKT XMAD:ALB XMAD:NTH XMAD:AZK XMAD:BST XMAD:TRE XMAD:ACX XMAD:ELE LLY JNJ MRK ABBV LSE:AZN XSWX:ROG XSWX:NOVN PFE AMGN XPAR:SAN
Traded in Other Exchanges
GIKLY:USA GIFOF:USA GIFLF:USA GRFS:USA GRFP:Mexico GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain OZTA:Germany
Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Website
https://www.grifols.com
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.